Plasma samples for analysis of axitinib and vascular endothelial growth factor ligand (VEGF) concentrations were collected on the same days as PET/CT scans: −3 to 0 days prior to dosing, after 12–14 days of dosing (week 2) and after 5–7 days of drug washout (week 3). VEGF concentrations were measured by a commercially available 96-well plate quantitative sandwich immunoassay (Quantikine® human VEGF, R&D Systems, Minneapolis, MN) according to manufacturer’s instructions. Axitinib plasma concentrations were measured by a validated LC/MS/MS as previously described [11 (link)].